Switch theme
Sign up to access all valuation multiples
ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. its geographical segments are Asia, Europe, and America.
1983
40
LTM Revenue $14.1M
LTM EBITDA $4.0M
$30.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ContextVision has a last 12-month revenue (LTM) of $14.1M and a last 12-month EBITDA of $4.0M.
In the most recent fiscal year, ContextVision achieved revenue of $12.8M and an EBITDA of $3.9M.
ContextVision expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ContextVision valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14.1M | XXX | $12.8M | XXX | XXX | XXX |
| Gross Profit | $14.1M | XXX | $12.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | $4.0M | XXX | $3.9M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $3.2M | XXX | $2.1M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $1.6M | XXX | $2.4M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ContextVision's stock price is NOK 5 (or $0).
ContextVision has current market cap of NOK 373M (or $36.5M), and EV of NOK 309M (or $30.2M).
See ContextVision trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.2M | $36.5M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ContextVision has market cap of $36.5M and EV of $30.2M.
ContextVision's trades at 2.4x EV/Revenue multiple, and 7.7x EV/EBITDA.
Equity research analysts estimate ContextVision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ContextVision has a P/E ratio of 23.7x.
See valuation multiples for ContextVision and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.5M | XXX | $36.5M | XXX | XXX | XXX |
| EV (current) | $30.2M | XXX | $30.2M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBIT | 10.1x | XXX | 14.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.7x | XXX | 15.1x | XXX | XXX | XXX |
| EV/FCF | 42.6x | XXX | 10.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialContextVision's last 12 month revenue growth is -2%
ContextVision's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
ContextVision's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ContextVision's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ContextVision and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | -15% | XXX | -24% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ContextVision acquired XXX companies to date.
Last acquisition by ContextVision was XXXXXXXX, XXXXX XXXXX XXXXXX . ContextVision acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ContextVision founded? | ContextVision was founded in 1983. |
| Where is ContextVision headquartered? | ContextVision is headquartered in Norway. |
| How many employees does ContextVision have? | As of today, ContextVision has 40 employees. |
| Is ContextVision publicy listed? | Yes, ContextVision is a public company listed on OSL. |
| What is the stock symbol of ContextVision? | ContextVision trades under CONTX ticker. |
| When did ContextVision go public? | ContextVision went public in 1997. |
| Who are competitors of ContextVision? | Similar companies to ContextVision include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of ContextVision? | ContextVision's current market cap is $36.5M |
| What is the current revenue of ContextVision? | ContextVision's last 12 months revenue is $14.1M. |
| What is the current revenue growth of ContextVision? | ContextVision revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of ContextVision? | Current revenue multiple of ContextVision is 2.3x. |
| Is ContextVision profitable? | Yes, ContextVision is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ContextVision? | ContextVision's last 12 months EBITDA is $4.0M. |
| What is ContextVision's EBITDA margin? | ContextVision's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of ContextVision? | Current EBITDA multiple of ContextVision is 7.9x. |
| What is the current FCF of ContextVision? | ContextVision's last 12 months FCF is $0.7M. |
| What is ContextVision's FCF margin? | ContextVision's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of ContextVision? | Current FCF multiple of ContextVision is 42.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
